RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018. Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018.
RedHill Biopharma Ltd.: The Strategic Expansion and Clinical Progress are in line with the Company’s plans. Stock Target Price Unchanged. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma Ltd.: The Strategic Expansion and Clinical Progress are in line with the Company’s plans. Stock Target Price Unchanged.
Energix Renewable Energies Ltd.: The revenues in H1 2017 attest the implementation of plans and expected growth in cash flows from projects. Target Price Unchanged. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnergix Renewable Energies Ltd.: The revenues in H1 2017 attest the implementation of plans and expected growth in cash flows from projects. Target Price Unchanged.
